EU regulation warding off life science investment – IDA chief

The rules are the first major overhaul of the EU’s medicines regulations in 20 years, which aim to make access to medicines more secure and affordable

Michael Lohan, IDA chief executive, said that Europe was becoming ‘too burdensome’ from a regulatory and approval perspective, which could impact innovation. Picture: Maxwells Dublin

The EU’s complicated regulations is putting off investors in life sciences and threatening innovation across the bloc, the head of IDA Ireland has said.

Michael Lohan said that new rules proposed by Brussels last year risked further widening the gap between the US and the EU on cutting-edge technologies.

He told the Financial Times the US regulatory system had become “more agile, more responsive” but added that “the European system, one could argue, has moved ...